tbuckley/cabot-search huggingface dataset:
Reply
Authors: Laurens A. van Kleef, Milan J. Sonneveld, Robert J. de Knegt
Journal: Hepatology (2022)

We thank Sun et al. for their interest in our manuscript, in which we showed that fatty liver disease (FLD) in an elderly population was not associated with increased mortality.1 Sun et al. expressed several potential concerns. The first concern is about the potential interplay between metabolic syndrome, cardiovascular disease, and FLD. These factors are interrelated and adjusting for these factors may attenuate individual effect estimates. To overcome this issue, we performed extensive analyses, using both a simple (age‐and‐sex adjusted) and fully adjusted models, all of which yielded similar results. Secondly, they cited a study reporting excess mortality in patients with biopsy‐proven NAFLD and suggest that these findings conflict with our results.2 However, two critical differences in study design account for these contrasting findings. First, the Swede nationwide cohort's mean age was 22 years lower than in our cohort. Furthermore, our study was performed in the general population, whereas the quoted study selected only patients with biopsy‐confirmed NAFLD. The Swedish study, therefore, reflects a younger hospital‐based population that required liver biopsy and cannot be compared with community‐dwelling elderly. The third concern is based on a study reporting different risks of liver‐related death among men and women across age strata, suggesting that these differences may have influenced our findings.3 First of all, it is important to note that we studied mortality risk among patients with FLD versus those without, whereas the referenced study reported absolute cause‐specific mortality rates in patients with NAFLD without a non‐NAFLD comparator. Interestingly, Lin et al. reported that <6% of deaths in elderly patients with NAFLD and <1% among patients with NAFLD without cirrhosis were attributable to liver disease.3 Importantly, these estimates may even be inflated because patients were enrolled based on ICD codes, thus reflecting a subset of patients who have already undergone liver health evaluation, unlike most patients with NAFLD in the general population. Nevertheless, we performed additional stratified analyses, which yielded consistent results. This underscores that our findings are robust and, taken together with the study by Lin et al., highlight the importance of other causes of death among (elderly) patients with FLD. Their final concern is the lack of liver histology in our cohort. Because population‐based studies of community‐dwelling subjects using liver biopsy are not feasible, noninvasive methods are the only option. Although misclassification of steatosis and fibrosis may occur with noninvasive methods, liver ultrasound has shown good specificity for hepatic steatosis and reflects clinical practice and guideline recommendations. In conclusion, we feel that our findings consistently show that among community‐dwelling elderly, ultrasound‐based presence of FLD is not associated with excess mortality.
Abstracts of the 28th Annual Conference of the International Society for Environmental Epidemiology (ISEE), 1-4 September 2016, Rome, Italy
Journal: Environmental Health Perspectives (2016)

The 28th annual conference of the International Society for Environmental Epidemiology was held 1 - 4 September 2016 in Rome, Italy. The conference theme was "Old and New Risks: Challenges for Environmental Epidemiology." The focus of this year's conference is current and future challenges in exposure assessment, study design, and data analyses.
Systolic Blood Pressure, Arterial Rigidity, and Risk of Stroke
Authors: William B. Kannel
Journal: JAMA (1981)

Based on prospective data from the Framingham study relating systolic pressure, diastolic pressure, age, and pulse-wave configuration to future stroke incidence, it would appear that isolated systolic hypertension predisposes to stroke independent of arterial rigidity. The prevalence of isolated systolic hypertension increased with age and with the degree of blunting of the dicrotic notch in the pulse wave. Subjects with isolated systolic hypertension experienced two to four times as many strokes as did normotensive persons. While diastolic pressure is related to stroke incidence, in the subject with systolic hypertension, the diastolic component adds little to risk assessment and in men, in this subgroup, appears unrelated to stroke incidence. (<i>JAMA</i>1981;245:1225-1229)
The Transition From a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk
Authors: Heba M. Ismail, David Cuthbertson, Stephen E. Gitelman, Jay S. Skyler, Andrea K. Steck, Henry Rodriguez, Mark Atkinson, Brandon M. Nathan, Maria J. Redondo, Kevan C. Herold, Carmella Evans-Molina, Linda A. DiMeglio, Jay Sosenko
Journal: Diabetes Care (2022)

To define the relationship between glucose and C-peptide during the progression to type 1 diabetes (T1D).We longitudinally studied glucose and C-peptide response curves (GCRCs), area under curve (AUC) for glucose, and AUC C-peptide from oral glucose tolerance tests (OGTTs), and Index60 (which integrates OGTT glucose and C-peptide values) in Diabetes Prevention Trial-Type 1 (DPT-1) (n = 72) and TrialNet Pathway to Prevention Study (TNPTP) (n = 82) participants who had OGTTs at baseline and follow-up time points before diagnosis.Similar evolutions of GCRC configurations were evident between DPT-1 and TNPTP from baseline to 0.5 years prediagnosis. Whereas AUC glucose increased throughout from baseline to 0.5 years prediagnosis, AUC C-peptide increased from baseline until 1.5 years prediagnosis (DPT-1, P = 0.004; TNPTP, P = 0.012) and then decreased from 1.5 to 0.5 years prediagnosis (DPT-1, P = 0.017; TNPTP, P = 0.093). This change was mostly attributable to change in the late AUC C-peptide response (i.e., 60- to 120-min AUC C-peptide). Median Index60 values of DPT-1 (1.44) and TNPTP (1.05) progressors to T1D 1.5 years prediagnosis (time of transition from increasing to decreasing AUC C-peptide) were used as thresholds to identify individuals at high risk for T1D in the full cohort at baseline (5-year risk of 0.75-0.88 for those above thresholds).A transition from an increase to a decrease in AUC C-peptide ∼1.5 years prediagnosis was validated in two independent cohorts. The median Index60 value at that time point can be used as a pathophysiologic-based threshold for identifying individuals at high risk for T1D.
Impotency, Sterility, and Artificial Impregnation.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns
Authors: Maximilian J. Mair, Annette Leibetseder, Gerwin Heller, Rainer Puhr, Erwin Tomasich, Sebastian Goldberger, Teresa Hatziioannou, Adelheid Wöhrer, Georg Widhalm, Karin Dieckmann, Martin Aichholzer, Serge Weis, Tim von Oertzen, Julia Furtner, Josef Pichler, Matthias Preusser, Anna S. Berghoff
Journal: Clinical Cancer Research (2022)

Abstract Purpose: The treatment of oligodendroglioma consists of tumor resection and radiochemotherapy. The timing of radiochemotherapy remains unclear, and predictive biomarkers are limited. Experimental Design: Adult patients diagnosed with isocitrate dehydrogenase (IDH)-mutated, 1p/19q-codeleted CNS WHO grade 2 and 3 oligodendroglioma at the Medical University of Vienna and the Kepler University Hospital Linz (Austria) in 1992 to 2019 were included. Progression-free (PFS) and overall survival (OS) between early postoperative treatment and initial observation were compared using propensity score–weighted Cox regression models. DNA methylation analysis of tumor tissue was performed using Illumina MethylationEPIC 850k microarrays. Results: One hundred thirty-one out of 201 (65.2%) patients with CNS WHO grade 2 and 70 of 201 (34.8%) with grade 3 oligodendroglioma were identified. Eighty-three of 201 (41.3%) patients underwent early postoperative treatment, of whom 56 of 83 (67.5%) received radiochemotherapy, 15 of 84 (18.1%) radiotherapy (RT) only and 12 of 83 (14.5%) chemotherapy only. Temozolomide-based treatment was administered to 64 of 68 (94.1%) patients, whereas RT + procarbazine, lomustine (CCNU), and vincristine (PCV) were applied in 2 of 69 (3.5%) patients. Early treatment was not associated with PFS [adjusted hazard ratio (HR) 0.74; 95% CI, 0.33–1.65, P = 0.459] or OS (adjusted HR: 2.07; 95% CI, 0.52–8.21, P = 0.302) improvement. Unsupervised clustering analysis of DNA methylation profiles from patients receiving early treatment revealed two methylation clusters correlating with PFS, whereas no association of clustering with O6-methylguanine methyltransferase (MGMT) promoter methylation, CNS WHO grade, extent of resection, and treating center could be observed. Conclusions: In this retrospective study, early postoperative treatment was not associated with improved PFS/OS in oligodendroglioma. The potentially predictive value of whole-genome methylation profiling should be validated in prospective trials.
Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016
Authors: Tamara A Sussman, Rebecca Knackstedt, Wei Wei, Pauline Funchain, Brian R Gastman
Journal: Journal for ImmunoTherapy of Cancer (2022)

To evaluate factors affecting the utilization of immunotherapy and to stratify results based on the approval of ipilimumab in 2011 and programmed death-1 inhibitors in 2014, an analysis of available data from the National Cancer Database (NCDB) was performed.The NCDB was analyzed to identify patients with stage IV melanoma from 2004 to 2016. Patients were categorized during the time periods 2004-2010, 2011-2014, and 2015-2016. Overall survival (OS) was analyzed by Kaplan-Meier, log-rank, and Cox proportional hazard models; IO status was analyzed using logistic regression.24,544 patients were analyzed. Overall, 5238 patients (21.3%) who received IO had improved median OS compared with those who did not (20.2 months vs 7.4 months; p<0.0001). Between 2004 and 2010, 9.7% received immunotherapy; from 2011 to 2014, 21.9% received immunotherapy; and from 2015 to 2016, 43.5% received immunotherapy. Three-year OS significantly improved in patients treated with IO across treatment years: 31% (95% CI 29% to 34%) from 2004 to 2010, 35% (95% CI 33% to 37%) from 2011 to 2014, and 46% (95% CI 44% to 48%) from 2015 to 2016 (p<0.0001). Survival was worse in patients who did not receive IO during these treatment years: 16% (15%-17%), 21% (20%-22%), and 27% (25%-28%), respectively. In the overall cohort, age <65 years, female gender, private insurance, no comorbidities, residence in metropolitan area, and treatment at academic centers were associated with better OS (p<0.0001 for all). In the multivariate analysis, receipt of IO from 2015 to 2016 was associated with age <65 years (OR 1.27, 95% CI 1.08 to 1.50), African American race (OR 5.88, 95% CI 1.60 to 28.58), lack of comorbidities (OR 1.43, 95% CI 1.23 to 1.66), and treatment at academic centers (OR 1.44, 95% CI 1.26 to 1.65) (p<0.05 for all).OS improved in patients with stage IV melanoma receiving IO, with the highest OS rate in 2015-2016. Our findings, which represent a real-world population, are slightly lower than recent trials, such as KEYNOTE-006 and CheckMate 067. Significant socioeconomic factors may impact receipt of IO and survival.
Correction: Management of granulomatous lobular mastitis: an international multidisciplinary consensus (2021 edition)
Authors: Qian-Qian Yuan, Shu-Yuan Xiao, Omar Farouk, Yu-Tang Du, Fereshte Sheybani, Qing Ting Tan, Sami Akbulut, Kenan Cetin, Afsaneh Alikhassi, Rami Jalal Yaghan, Irmak Durur-Subasi, Fatih Altintoprak, Tae Ik Eom, Fatih Alper, Mustafa Hasbahceci, David Martínez-Ramos, Pelin Seher Oztekin, Ava Kwong, Cedric W. Pluguez-Turull, Kirstyn E. Brownson, Shirish Chandanwale, Mehran Habibi, Liu-Yi Lan, Rui Zhou, Xian-Tao Zeng, Jiao Bai, Jun-Wen Bai, Qiong-Rong Chen, Xing Chen, Xiao-Ming Zha, Wen-Jie Dai, Zhi-Jun Dai, Qin-Yu Feng, Qing-Jun Gao, Run-Fang Gao, Bao-San Han, Jin-Xuan Hou, Wei Hou, Hai-Ying Liao, Hong Luo, Zheng-Ren Liu, Jing-Hua Lu, Bin Luo, Xiao-Peng Ma, Jun Qian, Jian-Yong Qin, Wei Wei, Gang Wei, Li-Ying Xu, Hui-Chao Xue, Hua-Wei Yang, Wei-Ge Yang, Chao-Jie Zhang, Fan Zhang, Guan-Xin Zhang, Shao-Kun Zhang, Shu-Qun Zhang, Ye-Qiang Zhang, Yue-Peng Zhang, Sheng-Chu Zhang, Dai-Wei Zhao, Xiang-Min Zheng, Le-Wei Zheng, Gao-Ran Xu, Wen-Bo Zhou, Gao-Song Wu
Journal: Military Medical Research (2022)
Alterations of Gut Microbiome, Metabolome, and Lipidome in Takayasu Arteritis
Authors: Luyun Fan, Junru Chen, Lili Pan, Xiaohong Xin, Bin Geng, Lirui Yang, Qian Wang, Wenjun Ma, Ying Lou, Jin Bian, Xiao Cui, Jing Li, Lu Wang, Zhenzhen Chen, Wenjie Wang, Changting Cui, Shuangyue Li, Qiannan Gao, Qirui Song, Yue Deng, Jiali Fan, Jiachen Yu, Huimin Zhang, Yafeng Li, Jun Cai
Journal: Arthritis & Rheumatology (2022)

Mounting evidence has linked microbiome and metabolome to systemic autoimmunity and cardiovascular diseases (CVDs). Takayasu arteritis (TAK) is a rare disease that shares features of immune-related inflammatory diseases and CVDs, about which there is relatively limited information. This study was undertaken to characterize gut microbial dysbiosis and its crosstalk with phenotypes in TAK.To address the discriminatory signatures, we performed shotgun sequencing of fecal metagenome across a discovery cohort (n = 97) and an independent validation cohort (n = 75) including TAK patients, healthy controls, and controls with Behçet's disease (BD). Interrogation of untargeted metabolomics and lipidomics profiling of plasma and fecal samples were also used to refine features mediating associations between microorganisms and TAK phenotypes.A combined model of bacterial species, including unclassified Escherichia, Veillonella parvula, Streptococcus parasanguinis, Dorea formicigenerans, Bifidobacterium adolescentis, Lachnospiraceae bacterium 7 1 58FAA, Escherichia coli, Streptococcus salivarius, Klebsiella pneumoniae, Bifidobacterium longum, and Lachnospiraceae Bacterium 5 1 63FAA, distinguished TAK patients from controls with areas under the curve (AUCs) of 87.8%, 85.9%, 81.1%, and 71.1% in training, test, and validation sets including healthy or BD controls, respectively. Diagnostic species were directly or indirectly (via metabolites or lipids) correlated with TAK phenotypes of vascular involvement, inflammation, discharge medication, and prognosis. External validation against publicly metagenomic studies (n = 184) on hypertension, atrial fibrillation, and healthy controls, confirmed the diagnostic accuracy of the model for TAK.This study first identifies the discriminatory gut microbes in TAK. Dysbiotic microbes are also linked to TAK phenotypes directly or indirectly via metabolic and lipid modules. Further explorations of the microbiome-metagenome interface in TAK subtype prediction and pathogenesis are suggested.
ETS1 governs pathological tissue-remodeling programs in disease-associated fibroblasts
Authors: Minglu Yan, Noriko Komatsu, Ryunosuke Muro, Nam Cong-Nhat Huynh, Yoshihiko Tomofuji, Yukinori Okada, Hiroshi I. Suzuki, Hiroyuki Takaba, Riko Kitazawa, Sohei Kitazawa, Warunee Pluemsakunthai, Yuichi Mitsui, Takashi Satoh, Tadashi Okamura, Takeshi Nitta, Sin-Hyeog Im, Chan Johng Kim, George Kollias, Sakae Tanaka, Kazuo Okamoto, Masayuki Tsukasaki, Hiroshi Takayanagi
Journal: Nature Immunology (2022)
Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation
Authors: Alan Kennedy, Erin Waters, Behzad Rowshanravan, Claudia Hinze, Cayman Williams, Daniel Janman, Thomas A. Fox, Claire Booth, Anne M. Pesenacker, Neil Halliday, Blagoje Soskic, Satdip Kaur, Omar S. Qureshi, Emma C. Morris, Shinji Ikemizu, Christopher Paluch, Jiandong Huo, Simon J. Davis, Emmanuel Boucrot, Lucy S. K. Walker, David M. Sansom
Journal: Nature Immunology (2022)

CD28 and CTLA-4 (CD152) play essential roles in regulating T cell immunity, balancing the activation and inhibition of T cell responses, respectively. Although both receptors share the same ligands, CD80 and CD86, the specific requirement for two distinct ligands remains obscure. In the present study, we demonstrate that, although CTLA-4 targets both CD80 and CD86 for destruction via transendocytosis, this process results in separate fates for CTLA-4 itself. In the presence of CD80, CTLA-4 remained ligand bound, and was ubiquitylated and trafficked via late endosomes and lysosomes. In contrast, in the presence of CD86, CTLA-4 detached in a pH-dependent manner and recycled back to the cell surface to permit further transendocytosis. Furthermore, we identified clinically relevant mutations that cause autoimmune disease, which selectively disrupted CD86 transendocytosis, by affecting either CTLA-4 recycling or CD86 binding. These observations provide a rationale for two distinct ligands and show that defects in CTLA-4-mediated transendocytosis of CD86 are associated with autoimmunity.
Workers’ Memorial Day — April 28, 2016
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Workers' Memorial Day, observed annually on April 28, recognizes workers who suffered or died because of exposures to hazards at work. In 2014, 4,679 U.S. workers died from work-related injuries. Although deaths from work-related injuries are captured by surveillance systems, most deaths from work-related illness are not. In 2007, an estimated 53,445 deaths from work-related illness occurred. In 2014, employers reported approximately 3 million nonfatal injuries and illnesses to private industry workers and 722,000 to state and local government workers; an estimated 2.7 million work-related injuries were treated in emergency departments, resulting in 113,000 hospitalizations (National Institute for Occupational Safety and Health (CDC-NIOSH), unpublished data, 2016).
Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: an observational cohort study
Authors: Morgane Mailhe, Anne-Lise Beaumont, Michael Thy, Diane Le Pluart, Ségolène Perrineau, Nadhira Houhou-Fidouh, Laurène Deconinck, Chloé Bertin, Valentine Marie Ferré, Marie Cortier, Clémentine De La Porte Des Vaux, Bao-Chau Phung, Bastien Mollo, Mélanie Cresta, Fabrice Bouscarat, Christophe Choquet, Diane Descamps, Jade Ghosn, François-Xavier Lescure, Yazdan Yazdanpanah, Véronique Joly, Nathan Peiffer-Smadja
Journal: Clinical Microbiology and Infection (2022)
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Authors: John W. Ostrominski, Muthiah Vaduganathan, Brian L. Claggett, Rudolf A. de Boer, Akshay S. Desai, Dan Dobreanu, Adrian F. Hernandez, Silvio E. Inzucchi, Pardeep S. Jhund, Mikhail Kosiborod, Carolyn S.P. Lam, Anna M. Langkilde, Daniel Lindholm, Felipe A. Martinez, Eileen O'Meara, Magnus Petersson, Sanjiv J. Shah, Jorge Thierer, John J.V. McMurray, Scott D. Solomon
Journal: European Journal of Heart Failure (2022)
Clinical and microbiological features of drowning-associated pneumonia: a retrospective multicentre cohort study
Authors: Florian Reizine, Agathe Delbove, Pierre Tattevin, Alexandre Dos Santos, Laetitia Bodenes, Pierre Bouju, Pierre Fillâtre, Aurélien Frérou, Guillaume Halley, Olivier Lesieur, Patricia Courouble, Florian Berteau, Jean Morin, Flora Delamaire, Rémy Marnai, Anthony Le Meur, Cécile Aubron, Jean Reignier, Arnaud Gacouin, Jean-Marc Tadié
Journal: Clinical Microbiology and Infection (2022)
Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria: A Randomized Clinical Trial
Authors: Viktor Rotbain Curovic, Mie Klessen Eickhoff, Teemu Rönkkö, Marie Frimodt-Møller, Tine Willum Hansen, Harald Mischak, Peter Rossing, Tarunveer Singh Ahluwalia, Frederik Persson
Journal: Diabetes Care (2022)

To evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on the kidney-risk urinary proteomic classifier (CKD273) in persons with type 2 diabetes (T2D) and albuminuria.In a double-blind, randomized, controlled, crossover trial, we assigned participants with T2D and urinary albumin to creatinine ratio (UACR) ≥30 mg/g to receive dapagliflozin or matching placebo added to guideline-recommended treatment (ClinicalTrial.gov identifier NCT02914691). Treatment periods lasted 12 weeks, when crossover to the opposing treatment occurred. The primary outcome was change in CKD273 score. Secondary outcomes included regression from high-risk to low-risk CKD273 pattern using the prespecified cutoff score of 0.154. The primary outcome was assessed using paired t test between end-to-end CKD273 scores after dapagliflozin and placebo treatment. The McNemar test was used to assess regression in risk category.A total of 40 participants were randomized and 32 completed the trial with intact proteomic measurements. Twenty-eight (88%) were men, the baseline mean (SD) age was 63.0 (8.3) years, mean (SD) diabetes duration was 15.4 (4.5) years, mean HbA1c was 73 (14) mmol/mol (8.8% [1.3%]), and median (interquartile range) UACR was 154 (94, 329) mg/g. Dapagliflozin significantly lowered CKD273 score compared with placebo (-0.221; 95% CI -0.356, -0.087; P = 0.002). Fourteen participants exhibited a high-risk pattern after dapagliflozin treatment compared with 24 after participants placebo (P = 0.021).Dapagliflozin added to renin-angiotensin system inhibition reduced the urinary proteomic classifier CKD273 in persons with T2D and albuminuria, paving the way for the further investigation of CKD273 as a modifiable kidney risk factor.